Will you lose weight after switching from Adderall to Vyvanse?
By
Dr Milena Locci de Oliveira (PhD)
Author bio
Dr Milena Locci de Oliveira is a Pharmacist and Doctor of Philosophy in Sciences from the University of São Paulo (USP). She has experience in microbiology, analytical toxicology, and clinical pharmacokinetics. She writes and reviews content on these topics.
Dr Milena’s Highlights:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration in the areas of Pharmacometrics and Population Pharmacokinetics, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
“Science can be translated, and it is essential that everyone has access to quality information to make informed decisions” – Dr Milena Oliveira, PhD.
Professional Experience:
With a decade-long career as a researcher, Dr Milena has amassed extensive experience in conducting research projects in microbiology, analytical toxicology, and clinical pharmacokinetics.
Her expertise also extends to the preparation of technical and scientific reports, literature reviews, data analysis, and scientific communication, both oral and written.
Dr Milena has served as a Clinical Pharmacist, providing expert supervision and guidance to teams during the challenging times of the COVID-19 pandemic, particularly in the ICUs of two reference hospitals for patient hospitalization.
In her most recent role, Dr Milena worked on the implementation of the deliberatives of the São Paulo State Government Pharmaceutical Assistance Coordination. These decisions were aimed at ensuring medication access within the Unified Health System.
A widely multidisciplinary background enabled Dr Milena to become a professional capable of integrating scientific knowledge into private initiatives, education, and healthcare, delivering consistent services in patient safety and population health.
Professional Memberships & Affiliations:
Dr Milena Oliveira is a member of the Regional Council of Pharmacy of the State of São Paulo, Brazil.
Education:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
Relevant Published Work & Citations:
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis. Nov 2020. 191:113-124.
Abstracts. CPT: Pharmacometrics & Systems Pharmacology. 2020 Nov; 9 (S1).
Pippa LF, Oliveira ML de, Rocha A, de Andrade JM, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis. 2020 Jun 5; 185:113-231.
Godoy ALPC, De Jesus C, De Oliveira ML, Rocha A, Pereira MPM, Larangeira DF, Lanchote VL, Barrouin-Melo SM. Determination of Allopurinol and Oxypurinol in Dogs Plasma by High-Performance Liquid Chromatography with an Ultraviolet Detector: Application for Pharmacokinetic Studies. J Chromatogr Sep Tech. 2017; 8 (4).
Clímaco EC, Oliveira ML de, Pitondo-Silva A, Oliveira MG, Medeiros M, Lincopan N, et al. Clonal complexes 104, 109 and 113 playing a major role in the dissemination of OXA-carbapenemase-producing Acinetobacter baumannii in Southeast Brazil. Infection, Genetics and Evolution. 2013 Oct;19:127–33.
Conference Papers:
Oliveira, M. L.; NARDOTTO, G. H. B.; PIPPA, L. F.; ROCHA, A.; SIMOES, B. P.; LANCHOTE, V. L. . Daunorubicin metabolism and urinary excretion in patients with acute myeloid leukemia. In: 84th Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) and the 20th Annual Meeting of the Association of the Clinical Pharmacology Germany (VKliPha), 2018, Göttingen. Naunyn-Schmiedeberg’s Arch Pharmacol, 2018. v. 391. p. S76-S76.
Oliveira, M. L.; NARDOTTO, G. H. B. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . The low contribution of urinary excretion in the elimination of daunorubicin and its metabolite daunorubicinol in patients with acute myeloid leukemia. In: 49th Brazilian Congress of Pharmacology and Experimental Therapeutics., 2017, Ribeirão Preto. Livro de Resumos, 2017. p. 64-64.
Oliveira, M. L.; PIPPA, L. F. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . Quantification of daunorubicin and its metabolite daunorubicinol in human plasma by LC-MS/MS. In: I International Meeting of Environmental Health and Toxicology (IMEHTOX), 2016, Ribeirão Preto. Livro de Resumos, 2016.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. . PFGE typing of Carbapenem-Resistant Acinetobacter baumannii isolated from different University Hospitals. In: V International Postgraduate and Research Symposium, 2012.
Clímaco, E.C. ; SILVA, A. P. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. Relação clonal entre linhagens de Acinetobacter baumannii produtoras de carbapenemases da família OXA em quatro hospitais no Brasil. In: XXI Latin American Congress of Microbiology, 2012, Santos. XXI Latin American Congress of Microbiology, 2012.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Darini A.L.C. . Dissemintion of OXA carbapenemases genes in carbapenem-resistant Acinetobacter baumannii in University Hospital of Juiz de Fora, MG. In: 8th CIFARP – International Congress of Pharmaceutical Sciences, 2011, Ribeirão Preto.
Clímaco, E.C. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Darini A.L.C. . Avaliação do sequenciamento parcial do gene rpoB e de seus flanqueadores para identificação de espécies de Acinetobacter na rotina laroratorial. In: 2° International Symposium on Clinical Microbiology, 2010, Florianópolis.
You can view some of Dr Milena’s work below and links to her professional profile.
Linkedin: https://www.linkedin.com/in/dra-milena-locci-de-oliveira-28986042/?locale=en_US
ResearchGate: https://www.researchgate.net/profile/Milena-Oliveira-6
Escavador: https://www.escavador.com/sobre/5394254/milena-locci-de-oliveira
Lattes: https://buscatextual.cnpq.br/buscatextual/busca.do
Scopus: https://www.scopus.com/authid/detail.uri?authorId=57199779361
Scholar: https://scholar.google.com/citations?view_op=list_works&hl=pt-BR&user=1YUBDIQAAAAJ
Will you lose weight after switching from Adderall to Vyvanse?
You may not lose more weight on Vyvanse after switching from Adderall. Both of these meds are Amphetamines and they both work in the same way. Adderall is associated with weight loss because it decreases your appetite and makes you burn more calories.
Vyvanse will do the exact same and you may not lose any more weight than you lost on Adderall. However, if Adderall did not suit you for some reason and your doctor thinks that Vyvanse could be a better option, you may lose weight on it.
One important thing to remember is that neither Adderall nor Vyvanse is a weight loss pill. These meds are categorized as control substances and they are never prescribed for the purpose of weight loss.
Make sure you talk to your healthcare provider if you’re concerned about your weight loss or gain. It’s in your best interest to stick to your doctor’s recommended directions.
Effects of Adderall on body weight
When it comes to its effects on body weight, Adderall can have both potential weight loss and weight gain effects, although the specific impact can vary from person to person.
Some individuals may experience weight loss while taking Adderall. This can be due to several reasons. First, Adderall is a stimulant that can suppress appetite, leading to reduced food intake (1,2).
Additionally, it can increase metabolism and energy expenditure, which can contribute to weight loss (3). Furthermore, Adderall may also cause gastrointestinal side effects, such as nausea or stomach upset, which can further impact food intake (4).
On the other hand, some individuals may experience weight gain while taking Adderall. It can affect the balance of neurotransmitters in the brain, including dopamine, which can influence reward pathways and appetite regulation.
n some cases, this can lead to increased cravings and overeating, resulting in weight gain. Additionally, Adderall may cause fluid retention or changes in body composition, leading to weight fluctuations.
Effects of Vyvanse on body weight
Vyvanse can also have different effects on body weight. Some people may experience weight loss while taking Vyvanse. This can occur due to several reasons.
Vyvanse is a stimulant that can suppress appetite, leading to reduced food intake, especially in people with binge eating disorders (5,6). When appetite is decreased, it can result in weight loss over time. However, it’s important to note that not everyone will experience weight loss while taking Vyvanse.
Vyvanse can also have other effects on the body that may indirectly impact weight. For example, it can increase focus and improve impulse control, which might lead to better adherence to a healthy diet and exercise routine, ultimately supporting weight management.
Which one is better for you, Adderall or Vyvanse?
The choice between Adderall and Vyvanse should be made in consultation with a healthcare provider. They can evaluate your specific needs, consider your medical history, and take into account any concerns you have about body weight.
The goal is to find the most suitable medication that effectively manages your symptoms while minimizing any unwanted effects on body weight. Adderall is known to have stronger appetite-suppressing effects compared to Vyvanse, thus can lead to greater weight loss.
However, it’s worth noting that individual responses can differ, and some people may not experience significant changes in weight while taking Adderall. This is why it’s best to rely on your doctor’s directions. You shouldn’t choose one medication over the other on your own.
Was this helpful?
References
1.-
Jeffers AJ, Benotsch EG. Non-medical use of prescription stimulants for weight loss, disordered eating, and body image. Eat Behav. 2014 Aug;15(3):414-8. doi: 10.1016/j.eatbeh.2014.04.019. Epub 2014 May 10. PMID: 25064292. https://pubmed.ncbi.nlm.nih.gov/25064292/
2.-
Hsieh YS, Yang SF, Kuo DY. Amphetamine, an appetite suppressant, decreases neuropeptide Y immunoreactivity in rat hypothalamic paraventriculum. Regul Pept. 2005 Apr 15;127(1-3):169-76. doi: 10.1016/j.regpep.2004.11.007. PMID: 15680483. https://pubmed.ncbi.nlm.nih.gov/15680483/
3.-
Jones JR, Caul WF, Hill JO. The effects of amphetamine on body weight and energy expenditure. Physiol Behav. 1992 Mar;51(3):607-11. doi: 10.1016/0031-9384(92)90187-7. PMID: 1523237. https://pubmed.ncbi.nlm.nih.gov/1523237/
4.-
Martin D, Le JK. Amphetamine. 2022 Aug 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 32310563. https://www.ncbi.nlm.nih.gov/books/NBK556103
5.-
Schneider E, Higgs S, Dourish CT. Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder. Eur Neuropsychopharmacol. 2021 Dec;53:49-78. doi: 10.1016/j.euroneuro.2021.08.001. Epub 2021 Aug 27. PMID: 34461386. https://pubmed.ncbi.nlm.nih.gov/34461386/
6.-
Fornaro M, Solmi M, Perna G, De Berardis D, Veronese N, Orsolini L, Ganança L, Stubbs B. Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials. Neuropsychiatr Dis Treat. 2016 Jul 25;12:1827-36. doi: 10.2147/NDT.S109637. PMID: 27524900; PMCID: PMC4966690. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966690/
